Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Biotech Firm ''Creating Innovative Solutions' for Female Health

The company's most advanced assets are discussed in a Dawson James Securities report. In a July 18 research note, Dawson James Securities analyst Jason Kolbert reported he assumed coverage on Daré Bioscience Inc. (DARE:NASDAQ) , and in doing so, rated it Bu...

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. In a Sept. 26 research note, Dawson James Securities analyst Jason Kolbert reported that IsoRay Inc. (ISR:NYSE.MKT) launched a new marketing campaign call...

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. In a Dec. 2 research note, Dawson James Securities analyst Jason Kolbert purported that Anavex Life Sciences Corp.'s (AVXL:NASDAQ) ANAV...

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...

Three COVID-19 Patients Treated with PLX Cells

Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. In a March 30 research note, Dawson James Securities analyst Jason Kolbert reported that three high-risk COVID-19 pati...

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued

A description of the asset and its potential are provided in a Dawson James report. In a July 11 research note, Dawson James Securities analyst Jason Kolbert reported that coverage of DelMar Pharmaceuticals Inc. (DMPI:NASDAQ) transferred to him and, subseq...

Coverage Initiated on 'Biotech Machine'

The compelling reasons behind those descriptors are explored in a Dawson James Securities report. In an Aug. 26 research note, analyst Jason Kolbert reported that DawsonJames Securities initiated coverage on Fortress Biotech Inc. (FBIO:NASDAQ) with a Buy rating and ...

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...
1 2 3 4 5 6